On November 15, 2021 Ascendis Pharma A/S (Nasdaq: ASND) provided an update on the Company’s previously reported $25 million American Depositary Shares (ADS) Share Repurchase Program. Each ADS represents one ordinary share of Ascendis Pharma A/S (Press release, Ascendis Pharma, NOV 15, 2021, View Source [SID1234595581]). The program was executed under Rules 10b-18 and 10b5-1 of the U.S. securities regulations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the program initiated on November 1, 2021, Ascendis Pharma A/S has repurchased shares for an amount up to $25 million in the period from November 1, 2021 to November 9, 2021 and the program is completed.

Since the announcement as of November 8th, 2021, the following transactions have been executed.

Trade Date

Number of ADS
Weighted Average
Purchase Price

Total Value*
Accumulated, last announcement 122,422 $19,763,252
November 8, 2021 26,800 $161.84 $4,338,140
November 9, 2021 5,615 $159.99 $898,492
Purchased under the program 154,837 $161.43 $24,999,884
*Total value includes fees and costs associated with the repurchase program.

Following these transactions, Ascendis Pharma A/S repurchased a total of 154,837 ADSs under the Share Repurchase Program.